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Nearly two thirds of persons suspected of having tickborne 
illness in central North Carolina, USA, were not tested for 
Ehrlichia. Failure to test may have resulted in a missed 
diagnosis for ≈13% of these persons, who were therefore 
substantially less likely to receive antimicrobial treatment 
and to have follow-up testing performed.
Incidence of spotted fever group Rickettsia (SFGR), which include the causative agent of Rocky Mountain 
spotted fever (RMSF), is high in North Carolina, USA (1). 
Entomologic studies, however, suggest that the principal 
vector in this state is the lone star tick (Amblyomma ameri-
canum), which is a major vector for Ehrlichia chaffeensis 
and E. ewingii (2,3). The clinical spectrum of Ehrlichia 
infection, which causes nonspecific signs and symptoms 
including fever, headache, and malaise, resembles that of 
RMSF (4,5). Therefore, we examined clinical practice pat-
terns associated with the evaluation and treatment of pa-
tients suspected of having tickborne illness to determine if 
Ehrlichia infection causes underrecognized tickborne ill-
ness in North Carolina.
The Study
We performed a retrospective chart review of all patients 
who had undergone serologic testing for tickborne illness 
at University of North Carolina hospitals and associated 
clinics during June 8–September 8, 2016. We abstracted 
demographic information, test results, and treatment plans 
for patients with signs and symptoms consistent with acute 
infection (i.e., fever, headache, myalgia) or recent tick ex-
posure. Patients were excluded if testing had been ordered 
for chronic symptoms, including fatigue or neurocognitive 
deficits. Testing for Borrelia burgdorferi (Lyme disease) 
was performed by chemiluminescent immunoassay (Dia-
sorin, Inc., Stillwater, MN, USA). Indirect immunofluores-
cence antibody (IFA) testing for SFGR was performed by 
using R. rickettsia–coated slides and a polyvalent conju-
gate, whereas testing for Ehrlichia was performed by using 
an IgG-based IFA (both from Biocell Diagnostics Inc, Bal-
timore, MD, USA). If testing for Ehrlichia was not ordered 
at the time of the initial healthcare visit, this testing was 
performed on stored serum (retrospective testing). Given 
potential cross-reactivity, we also tested retrospective sam-
ples for Anaplasma phagocytophilum. A positive test was 
defined as a positive IFA result with a subsequent IgG titer 
of >80 for SFGR and >64 for Ehrlichia.
We compared characteristics of the cohort by using 
the Student t-test for continuous variables and the Pearson 
χ2 test for categorical variables. We fit univariable Pois-
son regression models to examine associations between 
doxycycline prescriptions and test results. The study was 
approved by the University of North Carolina institutional 
review board.
We screened 226 records, from which 194 patients 
were included in the analysis (Table). The most com-
mon reason for patient exclusion was having been tested 
in response to longstanding symptoms (Figure). Tick ex-
posure was documented for 61 (61.6%) of 99 encounters, 
although many providers did not record exposure history. 
The most commonly reported signs and symptoms were fe-
ver (38.1%), headache (27.8%), and myalgia (21.7%). The 
median duration of symptoms for those reporting an illness 
was 6 days (interquartile range 3–14 days).
Most (91.8%) patients were seen in ambulatory clinics 
and emergency departments. Overall, most patients were 
tested for SFGR (154, 79.4%) and Lyme disease (128, 
66.0%), but testing for Ehrlichia was ordered for only 70 
(36.1%) patients.
A total of 154 patients were initially tested for SFGR 
and results for 37 (24.0%) were positive; 70 patients were 
initially tested for Ehrlichia and results for 9 (12.9%) 
were positive. Only 1 Lyme disease test result was 
positive. Of the 124 patients who did not initially have 
Ehrlichia testing performed, retrospective testing results 
were Ehrlichia positive for 25 (20.2%); none were posi-
tive for Anaplasma. Among those with a positive retro-
spective test result for whom results of a complete blood 
count or transaminase levels were available, 2 (12.5%) 
of 16 had concurrent thrombocytopenia and 1 (10.0%) 
of 10 had elevated transaminase levels. Convalescent-
phase serologic testing results were obtained for 24 
(12.5%) patients, among whom there was only 1 occur-
rence of a 4-fold titer increase in a patient with posi-
tive Ehrlichia titers. Convalescent-phase serologic test-
ing was more frequently ordered for patients for whom 
acute-phase serologic results for SFGR, Ehrlichia, or 
both were positive (19/24, 79.2%).
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Doxycycline was prescribed for half of all patients for 
whom treatment was known (94/188, 50.0%). Patients for 
whom acute SFGR serologic results were positive were 
more likely than those whose results were negative to re-
ceive doxycycline (odds ratio [OR] 7.52, 95% CI 2.73–
20.8; p<0.001), but this finding was not true with regard to 
patients with positive versus negative results for Ehrlichia. 
Of note, doxycycline was prescribed less frequently for 
patients with a positive retrospective Ehrlichia test result 
(30.4%) than for those with a positive provider-ordered test 
(77.8%) (OR 0.13, 95% CI 0.02–0.78; p = 0.03). Similarly, 
convalescent-phase serologic testing was performed less 
often for patients with a positive retrospective test result 
(16.0%) than for those with a positive provider-ordered test 
result (55.6%) (OR 0.15, 95% CI 0.03–0.85; p = 0.03).
Our results demonstrate that Ehrlichia accounted for 
a large proportion of reactive antibodies among a cohort 
of patients suspected of having tickborne illness in central 
North Carolina. These findings provide strong, albeit cir-
cumstantial, evidence that Ehlichia infection is as prevalent 
as SFGR infection. Yet, providers ordered Ehrlichia testing 
much less frequently than SFGR or even Lyme disease test-
ing, despite the low incidence of Lyme disease in the state. 
This disparity may be attributable to unfamiliarity with 
local vector epidemiology and to the greater attention given 
to RMSF and Lyme disease by the general population.
Our results show that testing strategies had a clear 
effect on patient care. Despite the recommendation that 
doxycycline be empirically given to patients suspected 
of having RMSF, our findings show that providers were 
significantly more likely to prescribe doxycycline when 
the acute-phase serologic test results were reactive (6). 
By extension, because providers were ordering testing for 
Ehrlichia less frequently, patients who were ultimately 
found to have positive retrospective serologic results were 
not identified during routine evaluation and thus were less 
likely to receive antimicrobial therapy.
Our study has several limitations, the most relevant of 
which is the reliance on single time point serologic testing for 
most patients. The absence of convalescent-phase serologic 
testing adversely affects our ability to discriminate acute in-
fection from prior exposure. The presence of thrombocyto-
penia or elevated transaminase levels suggests that at least a 
portion of patients found to have reactive antibodies by ret-
rospective testing had acute infections, but testing for these 
laboratory abnormalities was not performed for all patients. 
Thus, we may have misclassified some prior exposures as 
acute infections and some acute infections as noninfections.
 
Table. Patient characteristics stratified by provider-ordered Ehrlichia testing, North Carolina, 2016* 
Characteristic 
Tested for Ehrlichia, no. (%),  
n = 70† 
Not tested for Ehrlichia, no. (%),  
n = 124† p value 
Sex    
 M  39 (55.7) 64 (52.0) 0.48 
 F 31 (44.2) 60 (48.0)  
Setting    0.09 
 Outpatient clinic 42 (63.4) 57 (48.3)  
 Emergency department 16 (24.2) 47 (39.8)  
 Inpatient 8 (12.1) 14 (11.9)  
Provider medical specialty   0.001 
 Emergency medicine 13 (18.8) 43 (34.7)  
 Family medicine 16 (23.2) 20 (16.1)  
 Infectious diseases 9 (13.0) 2 (1.6)  
 Internal medicine 15 (21.7) 18 (14.5)  
 Other 16 (23.2) 41 (33.1)  
Reported signs and symptoms    
 Fever 27 (38.6) 47 (37.9) 0.93 
 Headache 22 (31.4) 32 (25.8) 0.40 
 Myalgia 11 (15.7) 31 (25.0) 0.13 
 Rash 12 (17.1) 27 (21.8) 0.44 
Tick exposure‡ 28 (41.2) 33 (27.7) 0.05 
Testing    
 SFGR 62 (88.6) 92 (74.2) 0.02 
 Lyme disease 48 (68.6) 80 (64.5) 0.57 
Positive test result    
 Ehrlichia 9 (12.9) 25 (20.2) 0.20 
 SFGR 15 (24.2) 22 (23.9) 0.97 
 Lyme disease 0 (0.0) 1 (1.3) 0.44 
Doxycycline prescribed 27 (39.7) 67 (55.8) 0.03 
Convalescent-phase serology performed 15 (21.7) 10 (8.1) 0.007 
*Boldface indicates significance at p<0.05. IQR, interquartile range; SFGR, spotted fever group Rickettsia.  
†Among those tested for Ehrlichia, median (IQR) age was 53.5 (33–67) y, and among those not tested for Ehrlichia, median (IQR) age was 46 (30–61.5) 
y (p = 0.48). Among those tested for Ehrlichia, duration of symptoms was 6.5 (3–14) d, and among those not tested for Ehrlichia, duration was 5.5 (3–14) 
d (p = 0.59). Numbers and percentages vary because some data were not available. 
‡Unable to determine exposure status for 24 (35.3%) of 68 patients tested for Ehrlichia and 64 (53.8%) of 119 patients not tested for Ehrlichia. 
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Further complicating the picture is the issue of cross-
reactivity, especially between members of SFGR, such as 
Rickettsia rickettsii and R. parkeri, and potentially with 
the newly classified R. amblyommatis (7), which is also 
transmitted by lone star ticks. The use of PCR for the di-
agnosis of Ehrlichia infection could have overcome issues 
related to E. ewingii cross-reactivity but was not routinely 
ordered and could not be performed on stored serum. We 
did, however, perform IFA testing for A. phagocytphilum 
on retrospective samples to ensure no cross-reactivity 
with Ehrlichia.
Our sampling strategy probably did not capture all 
suspected cases in the specified period. Patients with a 
compelling history and clinical signs and symptoms may 
have empirically received doxycycline without testing. 
This practice could have biased our sample such that the 
patients most likely to have acute infection were treated 
empirically, whereas testing was only performed only for 
those with less typical presentations.
Conclusions
Our results demonstrate that, when considering tickborne 
illnesses, providers in North Carolina consider ehrlichio-
sis less frequently than RMSF and Lyme disease, despite 
the relatively high seroprevalence of antibodies reactive 
against Ehrlichia spp. in our cohort. Statewide education 
efforts targeting primary care offices and emergency de-
partments are needed to improve provider awareness of 
and approaches to this potentially severe disease. Given 
the wide and growing distribution of lone star ticks, these 
findings are probably generalizable to much of the mid-
Atlantic United States (8).
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